# Eosinophilic Granulomatosis with Polyangiitis (EGPA)

## Pathophysiology
Rare immune disorder characterized by:
- **Hypereosinophilia** (hallmark)
- Vasculitis (blood vessel inflammation)
- Granuloma formation
- Multi-organ involvement

**Serology**: 30-50% ANCA-positive

## Clinical Presentation - Phasic Development
**Prodromal Phase**:
- **Late-onset or worsening asthma** (most patients)
- Allergic rhinitis
- Sinusitis

**Systemic Vasculitic Phase**:
- Fever, fatigue
- Joint/muscle pain

## Systemic Involvement
**Lungs**: Primary target
**Peripheral Nerves**: Numbness, tingling, pain
**Skin**: Rashes, nodules
**GI Tract**: Abdominal symptoms
**Heart**: **Major cause of death** if untreated

## Treatment
**First-line**: Corticosteroids
**Severe Cases**:
- Immunosuppressants
- Biologic agents: mepolizumab, benralizumab (target eosinophils)

## Clinical Pearl
Think EGPA in patient with:
- Late-onset asthma
- Sinusitis
- Peripheral neuropathy
- Eosinophilia

## Related Concepts
See also: [[Granulomatosis with Polyangiitis (GPA)]] [[ANCA-Associated Vasculitides]] [[Asthma - Late Onset]]

## Tags
#rhinology #GranulomatousDiseases #autoimmune #ConnectiveTissueDisorders